CAN
SUPN icon

Cetera Advisor Networks’s Supernus Pharmaceuticals SUPN Stock Holding History

Cetera Advisor Networks’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-269
Closed -$6K – 2817
2020
Q2 		$6K Buy
+269
New +$5.94K ﹤0.01% 2936

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Cetera Advisor Networks's SUPN Position: Q3 2020 in Review

Cetera Advisor Networks sold out of Supernus Pharmaceuticals (SUPN) in Q3 2020, closing a stake of 269 shares — an estimated $6K sold.

Cetera Advisor Networks first reported a position in SUPN in Q2 2020 and held it in 1 quarter. The position peaked at $6K in Q2 2020. 209 funds tracked by Wall St. Rank hold SUPN as of Q3 2020.

  • Cetera Advisor Networks reported no remaining Supernus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Cetera Advisor Networks sold 269 Supernus Pharmaceuticals shares in Q3 2020, an estimated $6K.
  • Cetera Advisor Networks first reported a position in Supernus Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Cetera Advisor Networks's Supernus Pharmaceuticals position peaked at $6K in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2020.

Based on Cetera Advisor Networks's 13F filing for Q3 2020, filed 13 Nov 2020.